Clinical trials · source year
8 selected, source-linked clinical trial records dated 2011. This is selective source coverage, not a complete timeline.
8 selected records.
4 connected profiles.
8 distinct public records.
Cited chronology
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00557310 at 2026-07-30T22:15:58.883Z. Its registry update date was 2011-11-11, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT00797823 at 2026-07-30T22:15:58.887Z. Its registry update date was 2011-10-07, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00761332 at 2026-07-30T22:15:58.887Z. Its registry update date was 2011-06-21, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00343252 at 2026-07-30T22:15:58.895Z. Its registry update date was 2011-05-26, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00696644 at 2026-07-30T22:15:58.886Z. Its registry update date was 2011-05-09, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00439244 at 2026-07-30T22:15:58.884Z. Its registry update date was 2011-04-20, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT00850564 at 2026-07-30T22:15:58.888Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗
Bremelanotide
PeptideScanner retained ClinicalTrials.gov record NCT00425256 at 2026-07-30T22:15:58.882Z. Its registry update date was 2011-02-23, and PeptideScanner's reviewed identity mapping was bremelanotide.
Source: ClinicalTrials.gov ↗